Claims
- 1. A transgenic mouse comprising a disruption in a PPAR gene.
- 2. A transgenic mouse comprising a disruption in a PPAR gene, wherein there is no native expression of PPAR gene.
- 3. The transgenic mouse of claim 2, wherein the disruption is heterozygous.
- 4. The transgenic mouse of claim 2, wherein the disruption is homozygous.
- 5. The transgenic mouse of claim 4, wherein the transgenic mouse exhibits increased pain sensitivity.
- 6. The transgenic mouse of claim 4, wherein the transgenic mouse exhibits a neurological abnormality.
- 7. The transgenic mouse of claim 6, wherein the abnormality is present in the brain, cerebrum, or ventricle.
- 8. The transgenic mouse of claim 7, wherein the abnormality comprises dilation of the brain, cerebrum, or ventricle.
- 9. A method of producing a transgenic mouse comprising a disruption in a PPAR gene, the method comprising:
(a) providing a murine stem cell comprising a disruption in a PPAR gene; and (b) introducing the murine stem cell into a pseudopregnant mouse, wherein the pseudopregnant mouse gives birth to a transgenic mouse.
- 10. The transgenic mouse produced by the method of claim 9.
- 11. A targeting construct comprising:
(a) a first polynucleotide sequence homologous to at least a first portion of a PPAR gene; (b) a second polynucleotide sequence homologous to at least a second portion of a PPAR gene; and (c) a selectable marker.
- 12. A cell comprising a disruption in a PPAR gene, the disruption produced using the targeting construct of claim 11.
- 13. A cell derived from the transgenic mouse of claim 2.
- 14. A cell comprising a disruption in a PPAR gene.
- 15. The cell of claim 14, wherein the cell is a stem cell.
- 16. The cell of claim 15, wherein the stem cell is an embryonic stem cell.
- 17. The cell of claim 16, wherein the embryonic stem cell is a murine cell.
- 18. A method of identifying an agent that modulates pain, the method comprising:
(a) contacting a test agent with PPAR; and (b) determining whether the agent modulates PPAR.
- 19. A method of identifying an agent that modulates pain, the method comprising:
(a) contacting a test agent with a PPAR molecule; and (b) determining whether the agent modulates the PPAR molecule.
- 20. A method of identifying an agent that modulates pain, the method comprising:
(a) contacting a test agent with a PPAR molecule; and (b) determining whether the agent modulates the PPAR molecule.
- 21. A method of identifying an agent that modulates a phenotype selected from the group consisting of pain, the method comprising:
(a) administering a test agent to an animal exhibiting a phenotype selected from the group consisting of pain; and (b) determining whether the agent modulates pain.
- 22. A method of identifying a potential therapeutic agent for the treatment of pain, the method comprising:
(a) administering the potential therapeutic agent to a transgenic mouse comprising a disruption in a PPAR gene; and (b) determining whether the potential therapeutic agent modulates pain.
- 23. A method of identifying a potential therapeutic agent for the treatment of pain, the method comprising:
(a) contacting the potential therapeutic agent with PPAR; (b) determining whether the agent modulates PPAR, wherein modulation of PPAR identifies a potential therapeutic agent for the treatment of pain.
- 24. A method of identifying a potential therapeutic agent for the treatment of pain, the method comprising:
(a) contacting the potential therapeutic agent with a PPAR molecule; (b) determining whether the agent modulates the PPAR molecule, wherein modulation of the PPAR molecule identifies a potential therapeutic agent for the treatment of pain.
- 25. A method of evaluating a potential therapeutic agent capable of affecting a condition associated with a mutation in a PPAR gene, the method comprising:
(a) administering the potential therapeutic agent to a transgenic mouse comprising a disruption in a PPAR gene; and (b) evaluating the effects of the agent on the transgenic mouse.
- 26. A method of evaluating a potential therapeutic agent capable of affecting a condition associated with a mutation in a PPAR gene, the method comprising:
(a) contacting the potential therapeutic agent with PPAR; (b) evaluating the effects of the agent on the PPAR.
- 22. A method of identifying an agent capable of modulating pain, the method comprising:
(a) providing a first preparation derived from the mouse of claim 2;(b) providing a second preparation derived from a wild-type mouse; (c) contacting a test agent with the first and second preparations; and (d) determining whether the agent interacts with the first and second preparations,
wherein interaction with the second preparation in the absence of interaction with the first preparation identifies a potential therapeutic agent for the treatment of pain.
- 23. A therapeutic agent for treating pain, wherein the agent modulates PPAR.
- 24. A therapeutic agent for treating pain, wherein the agent is an agonist or antagnonist of PPAR.
- 25. A pharmaceutical composition comprising PPAR.
- 26. A method of preparing a pharmaceutical composition for a condition associated with a function of PPAR, the method comprising:
(a) identifying a compound that modulates PPAR; (b) synthesizing the identified compound; and (c) incorporating the compound into a pharmaceutical carrier.
- 27. The method of claim 26, wherein the condition is pain.
- 28. Phenotypic data associated with a transgenic mouse comprising a disruption in a PPAR gene, wherein the phenotypic data is in an electronic database.
RELATED APPLICATIONS
[0001] This application is a continuation-in-part to copending U.S. application Ser. No. 10/013,807, filed Dec. 10, 2001, which claims priority to U.S. Provisional Application No. 60/254,916, filed Dec. 11, 2000, the entire contents of each are incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60254916 |
Dec 2000 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
10013807 |
Dec 2001 |
US |
Child |
10179403 |
Jun 2002 |
US |